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Purpose: Precise estimation of creatinine clearance in obese individuals relies on the   appropriate 
assessment of lean body weight (LBW). Anthropometric methods of predicting LBW have not 
been validated in morbidly obese populations.
Patients and methods: Using an existing dataset of anthropometric data for a female cohort 
with morbid obesity who had undergone measured FFW with dual energy absorptiometry, we 
evaluated the performance of five previously reported estimating equations for the prediction 
of LBW. Linear regression was used to derive a new LBW prediction formula and was then 
compared with the other formulae.
Results: Seventy females (mean [standard deviation] age, weight, and body mass index 43.0 
[11.0] years, 128.1 [13.8] kg, and 48.3 [4.8] kg/m², respectively) were identified. LBW as 
estimated by the method of Garrow and Webster correlated well (r = 0.87) with measured 
mass while demonstrating the highest accuracy, best precision, and smallest bias (93%, 2.1 kg, 
and 2.9 kg, respectively; P , 0.0001 for all comparisons). The derived formula further improved 
bias, precision, and accuracy.
Conclusion: Among females with morbid obesity, most previously reported estimating equa-
tions for LBW predicted FFW poorly. These findings have important clinical implications for 
the assessment of kidney function and for safe and effective drug dosing.
Keywords: body composition, body weight, creatinine clearance, kidney function, lean body 
mass, obesity, pharmacokinetics
Introduction
At extremes of weight, misapplication of commonly used clinical tools developed in 
normal-weight populations may have serious adverse consequences.1 There is a need 
for clinically useful and accurate methods of estimating renal function among patients 
with morbid obesity (body mass index [BMI] $ 40 kg/m2) for the purpose of safe 
and effective drug dosing, monitoring of kidney function longitudinally, and effec-
tive risk counseling. In this population, estimation of renal function is problematic, 
as commonly used formulae perform poorly at extremes of weight.2–4 Estimations 
of creatinine clearance using adjusted body weight (ABW) may represent a better 
assessment of kidney function than estimations of glomerular filtration rate using 
the Modification of Diet in Renal Disease estimating formula5 among patients with 
morbid obesity. Recently, several investigators have reported improved renal func-
tion estimates in obese (BMI $ 30 kg/m2) individuals using the Cockcroft-Gault 
creatinine clearance formula6 with adjustment for lean body weight (LBW) either 
by direct fat-free weight (FFW) measurement or by way of an estimating formula.7,8 International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Whether this applies to patients with morbid obesity is not 
clear, as the relationship between BMI and lean weight is 
not linear.9
Although direct measurement of FFW can be performed 
in several ways – to include dual energy absorptiometry 
(DEXA) – such methods are not practical for routine clinical 
use, due to complexity and cost.10–12 It is expected that LBW 
will overestimate fat-free mass (FFM) by 3%–5%, given that 
measurement of the latter does not include the normal adipose 
tissue surrounding muscle and nerves in a lean individual. 
However, use of LBW could serve as a clinically useful sur-
rogate for FFM for calculation of clearances of endogenous 
creatinine, as this substance distributes mainly in muscle 
and interstitial and vascular spaces.3,13 Various formulae for 
estimating LBW have been reported,14–21 but none has been 
developed or validated for specific use in a population of 
patients with morbid obesity.
This study evaluates the ability of previously reported 
alternative body size descriptor (ABSD) estimating 
formulae to predict measured FFW by DEXA in a cohort 
of female, morbidly obese patients enrolled in a weight 
management program at a tertiary medical center in 
  Central Pennsylvania. We did not limit the identification 
of previously reported formulae to those estimating LBW 
only, as the primary goal of this study was to identify 
a clinically useful estimating tool that could be employed 
in the Cockcroft and Gault creatinine clearance equa-
tion. As a secondary goal, we wished to improve upon 
the estimation of LBW in our own population through 
the development of a novel LBW estimating equation 
based on anthropometric and clinical data from our study 
population.
Material and methods
subjects
The study was reviewed and approved under “exempt” 
status by the Geisinger Medical Center Institutional Review 
Board in May 2010. The study uses existing data from a 
cohort of 70 adult (aged $18 years) morbidly obese (BMI 
of $40.0 kg/m²) female patients who participated in a feasi-
bility project evaluating the use of preoperative DEXA body 
composition scanning between May 2005 and January 2006 
while undergoing evaluation in a comprehensive weight 
management clinic prior to bariatric surgery at Geisinger 
Medical Center.22 The database that served as the source 
for this study includes demographic, clinical, outcomes, 
and claims information, including detailed anthropometric 
measurements, and has been previously validated.23–27
Anthropometric measurements
Body composition measurements (fat mass, lean mass, and 
bone mass) were made with a Hologic Series 4500 W   Fan 
Beam X-ray Bone densitometer (Hologic, Inc Bedford, 
MA). Measurements were performed on subjects   following 
the removal of all metal accessories. Scanners were 
  calibrated daily prior to patient use, using standard phantom 
  measurements. Patients were weighed at each clinic visit 
in the weight management clinic wearing hospital gowns. 
All weights are expressed in kilograms (kg). Height (Ht) 
in centimeters (cm) was measured at the initial clinic visit 
and not repeated subsequently. From the above measure-
ments, BMI = Wt/(Ht × 100)² and ideal body weight (IBW) 
(IBW = 45.4 + 0.89 × [Ht - 152.4])28 were calculated. LBW 
in the context of this study refers to the weight of lean tis-
sue, including the normal amount of fat contained in a lean 
individual (approximately 3% in males and 5% in females),17 
whereas FFW refers to the weight of lean tissue stripped 
of all fat, including the fat content of nervous system, cell 
membranes, and bone marrow.
selection of LBW estimating equations  
and assessment of performance
In order to identify previously reported estimations for LBW, 
we performed a literature search using Ovid   MEDLINE® 
(1950 to July Week 2, 2010) using the following search terms: 
body composition, morbid obesity, obesity, kidney function 
tests, glomerular filtration rate, lean body weight estimation, 
creatinine clearance, and pharmacokinetics. References of 
pertinent articles were also searched for studies describing 
LBW estimating equations for use in obese subjects. No 
method of estimating LBW exclusively in morbidly obese 
subjects was identified; five ABSD equations for the nonmor-
bidly obese populations were identified and assessed for the 
purposes of this analysis (Table 1). For the ABSD formula 
initially proposed by Karkeck,15 two   versions were used in 
this study, one using the original reported equation with a cor-
rection factor of 0.25, and a second with a correction factor 
of 0.5, as the latter reportedly improves caloric expenditure 
prediction and drug clearance in obese individuals when 
compared with the original equation.16,29 In addition, a sixth 
equation developed in our patient population was used to 
estimate FFW (FFW[GEISINGER]). Thus, each of our subjects had 
one measured FFW (FFW[DEXA]) and six LBW estimations, 
each using a different ABSD.
To compare the ability of each individual ABSD to pre-
dict FFW[DEXA], we calculated correlation, bias, precision, 
and accuracy.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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statistical analyses
Continuous data are reported as means and standard 
  deviations (SDs), whereas categorical variables are expressed 
as frequencies. When appropriate, the distributions of each 
continuous variable were examined for a symmetrical, 
bell-shaped distribution (ie, the normal distribution) and 
homoscedasticity (ie, equality of variance). Bias, precision, 
accuracy, and the Pearson correlation coefficient (r) were 
calculated for each estimating equation using FFW[DEXA] as 
the gold standard. Bias was defined as the absolute value of 
the difference between the estimated LBW and FFW[DEXA] 
(also known as absolute bias). Precision was defined as the 
SD of the absolute bias. Accuracy was calculated as the 
percentage of patients who had an estimated FFM within 
10% of the FFW[DEXA].
Differences in bias and accuracy were compared between 
ABSDs using a paired t-test and McNemar’s test. This was 
done by comparing the ABSD formula that performed the best 
(ie, with the least bias or with the highest accuracy) against 
all other ABSD formulae in a pairwise fashion.   Differences 
in precision among the various ABSDs were not tested. 
To determine whether estimating formula performance was 
similar for different levels of obesity, the bias, precision, 
accuracy, and correlation coefficient were also calculated 
after stratifying by BMI subcategories (40.0–44.9 kg/m², 
45.0–49.9 kg/m², $50.0 kg/m²).
Agreement between measured and estimated LBW values 
was assessed using the method of Bland and Altman,30 in 
which the difference between estimated LBW and FFW[DEXA] 
is plotted against the FFW[DEXA]. A positive difference sug-
gests an overestimation of the formula, whereas a nega-
tive difference suggests an underestimation. The limits of 
agreement were calculated as the bias plus two times the 
precision.
In exploratory analysis, linear regression was used to 
determine whether a new ABSD could be derived that out-
performed existing ABSDs. BMI, total body weight (TBW), 
Ht, and IBW were considered for inclusion in the regression 
model and the minimal subset of measures that maximized 
the model r-squared was retained.
All statistical analyses were performed using SAS® 
  software (version 9.2, Cary, NC).
Results
Seventy morbidly obese female patients underwent body 
composition DEXA. Patient characteristics and major comor-
bid conditions are presented in Table 2. All patients were 
Caucasian, with a mean age of 43 years. Thirty-six   percent International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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had hypertension, one-third had hyperlipidemia, and 
21% were diabetics. The majority (94%) of patients had 
preserved renal function (estimated glomerular filtration 
rate) calculated using the   four-variable Modification of 
Diet in Renal Disease equation31 (.60 mL/min/1.73 m²). 
The remaining four patients had estimated glomerular 
filtration rates 42.9, 43.7, 51.2, and 55.4 mL/min/1.73 m², 
respectively.
Results of individual formula performance are presented 
for the overall population in Table 3 and for subcategories 
of BMI in Table 4. FFM[Garrow], the ABW formulae, and 
LBW[Janmahasatian] correlated well with FFW[DEXA] (r . 0.80). In 
contrast, LBW[Hume] and LBM[Moore] correlated poorly.
Beyond correlation, the performance of equations other 
than FFM[Garrow] was quite poor. The overall mean bias was 
smallest for the FFM[Garrow] equation (P , 0.0001 for pairwise 
comparisons). This equation also had the highest accuracy 
(P , 0.0001 for pairwise comparisons) and best precision. 
Bias, precision, and accuracy were lower for the BMI-based 
equations (LBW[Janmahasatian] and LBW[Hume]). LBW[Janmahasatian] 
did maintain its level of accuracy in BMI categories between 
40.0–44.9 kg/m² and 45.0–49.9 kg/m² but not in subjects with 
BMI $ 50.0 kg/m².
A Bland–Altman plot for the FFM[Garrow] equation is shown 
in Figure 1. There is an inverse relationship between bias and 
incremental measured FFW (r = -0.73).
In regression analysis performed to identify an improved 
prediction formula, the combination of body composition 
measures that optimized the prediction of FFW was TBW 
and Ht. The resulting equation was FFW[GEISINGER] = -11.41 + 
(0.354 × TBW) + (11.06 × Ht). Though not significantly dif-
ferent from FFM[Garrow], this equation had the least bias, the 
best precision, and the highest accuracy.
Discussion
LBW estimation in morbidly obese individuals presents 
unique challenges. In our exclusively Caucasian female 
population, not all previously reported ABSD estimating 
formulae performed well for the determination of FFW as 
measured by DEXA body composition testing.
One estimating formula in particular, FFM[Garrow], outper-
formed others. This regression equation was developed in 
a predominantly (81%) female population with mean (SD) 
BMI 27.2 (7.8) kg/m2 against a gold standard consisting of 
the average body fat measurement obtained by three differ-
ent methods (tissue density, total body water using a tritiated 
water dilution method, and total body potassium using the 
40K isotope gamma spectrometry method).14 It is interesting 
that each of these methods measures a slightly different 
lean weight, making the combination of the three methods 
a potentially robust assessment of the true lean mass. In our 
cohort, this equation demonstrated the most optimal perfor-
mance characteristics for the overall population with morbid 
obesity as well as within each subcategory of BMI.
Other ABSDs performed suboptimally, though several 
formulae incorporating BMI (LBW[Janmahasatian] and LBW[Hume]) 
performed modestly well across some of the study metrics. 
The formula developed by Janmahasatian et al18 was devel-
oped using FFW[DEXA] as a gold standard in a gender-balanced 
Australian population that was predominantly (70%) over-
weight (BMI $ 25). This equation has subsequently been 
Table 2 characteristics of population of morbidly obese female 
patients undergoing DeXA (n = 70)
Characteristic Mean (SD)
Age (y) 43 (11)
Weight (kg) 128.1 (13.8)
height (cm) 162.8 (5.4)
serum creatinine (mg/dL) 0.8 (0.2)
BMI (kg/m2) 48.3 (4.8)
Waist circumference (cm)a 128.1 (10.2)
FFW[DeXA] (kg) 63.4 (6.9)
Comorbid conditions N (%)
hypertension 25 (36)
hyperlipidemia 22 (31)
Diabetes 15 (21)
Obstructive sleep apnea 6 (9)
cerebrovascular disease 2 (3)
Atherosclerotic cardiovascular disease 1 (1)
chronic renal disease 1 (1)
Note: aData available for 53 patients.
Abbreviations: BMI, body mass index (kg/m²); DeXA, dual energy absorptiometry; 
FFW, fat-free weight (kg).
Table 3 correlation, bias, and accuracy of reported estimating 
equations  for  LBW  compared  with  DeXA-derived  lean  body 
weight for female patients with morbid obesity (BMI . 40 kg/m²)
Formula All patients (n = 70)
Biasa Precisionb Accuracyc r
FFM[garrow] 2.9 2.1 93% 0.87
ABW0.25 9.7 3.8 17% 0.84
ABW0.5 28.0 4.1 0% 0.87
LBW[Janmahasatian] 6.0 3.6 54% 0.85
LBW[hume] 18.7 10.0 4% -0.15
FFW[geIsINgeR] 2.8 1.8 97% 0.87
Notes:  aBias = mean absolute bias (mean absolute value of difference between 
formula-  and  DeXA-derived  LBW  for  each  individual);  bPrecision  =  standard 
deviation of mean absolute bias; cAccuracy = percentage of estimations within 10% 
of the FFW[DeXA].
Abbreviations: ABW, adjusted body weight (kg); BMI, body mass index (kg/m²); 
DeXA, dual energy absorptiometry; FFM, fat-free mass (kg); FFW, fat-free weight (kg); 
LBW, lean body weight (kg).International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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shown to eliminate the bias of Cockcroft–Gault against both 
the creatinine and the inulin clearances when used instead 
of measured weight.7,8 Though this equation estimates inulin 
and creatinine clearance fairly well in obese populations,7,32 it 
did not estimate measured FFW as well as the FFM[Garrow] in 
our population of morbidly obese females. Consistent with 
the observation of declining performance as BMI increases 
for this formula, our results indicate that at incrementally 
higher BMI, LBW[Janmahasatian] predicts FFW poorly. Thus, 
its applicability to individuals with morbid obesity may be   
limited.
Weight-based estimating equations had the poorest 
performance in our study. The ABW formulae with various 
correction factors – although commonly used in nutrition 
practice for various resting energy calculations – are based 
on the assumption that excess weight in obesity is linearly 
increased from the IBW, an assumption that is physiologically 
flawed. Amato et al33 evaluated the accuracy and precision of 
using ABW (with a correction factor of 0.5) in 113 morbidly 
obese (mean ± SD BMI 52 ± 9 kg/m²) patients in a surgical 
intensive care unit and observed significant bias and poor 
precision of this body size descriptor for the prediction of 
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Figure 1 Bland–Altman plot representing absolute differences between lean weight estimations using FFM[garrow] equation vs measured FFW[DeXA] by BMI category.
Abbreviations: BMI, body mass index (kg/m²); DeXA, dual energy absorptiometry; FFM, fat-free mass (kg); FFW, fat-free weight (kg).
Table 4 correlation, bias, precision, and accuracy of reported estimating equations for LBW compared with dual energy absorptiometry-
derived lean body weight for female patients with extreme obesity (BMI . 40 kg/m²), by BMI category
Formula BMI 40.0–44.9 
(N = 20)
BMI 45.0–49.9 
(N = 27)
BMI $ 50.0 
(N = 23)
Bias Precision Accuracy r Bias Precision Accuracy r Bias Precision Accuracy r
FFM[garrow] 3.4 1.9 90% 0.87 2.6 2.2 89% 0.78 2.9 2.1 100% 0.86
ABW0.25 11.1 3.6 5% 0.86 9.8 3.9 11% 0.77 8.3 3.4 35% 0.81
ABW0.5 26.1 3.5 0% 0.87 27.5 4.4 0% 0.78 30.4 2.8 0% 0.87
LBW[Janmahasatian] 4.6 3.2 65% 0.87 5.4 3.1 63% 0.77 7.9 3.8 35% 0.81
LBW[hume] 9.4 4.6 15% 0.77 16.2 4.3 0% 0.59 29.7 7.7 0% -0.01
FFW[geIsINgeR] 3.2 1.7 95% 0.87 2.8 2.0 96% 0.78 2.6 1.5 100% 0.87
Abbreviations: ABW, adjusted body weight (kg); BMI, body mass index (kg/m²); FFM, fat-free mass (kg); FFW, fat-free weight (kg); LBW, lean body weight (kg).International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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measured resting energy expenditure. Although a direct 
relationship between calorimetric testing and measured FFW 
cannot be assumed, our results are congruent with those of 
Amato et al.
The clinical significance of our study findings is illus-
trated by comparing the Cockcroft and Gault-estimated 
creatinine clearance using LBW obtained from each of the 
reported and derived formulae with the clearance measure-
ment calculated using FFM from DEXA body composition 
scanning (Table 5). As is readily apparent, the range of 
calculated creatinine clearance using the various formulae 
is alarmingly broad. Finding and using the right lean weight 
estimation formula for the morbidly obese population is 
essential for safe health care delivery.
We derived a formula that improved the performance of 
FFM prediction and best approximated the estimated crea-
tinine clearance calculation, at least among our own popula-
tion of female patients with morbid obesity. This prediction 
formula should be tested and validated in other populations 
prior to clinical application.
We acknowledge that not all formulae used in our 
analysis were originally developed to measure the same 
body compartment, especially formulae such as ABW with 
various CF. Although this can explain the bias, it cannot 
account for the poor precision and accuracy in predict-
ing FFW[DEXA]. Our intention was to evaluate previously 
reported formulae developed to estimate alternative body 
weight descriptors for their potential to predict FFW in a 
population of morbidly obese females. The goal was not to 
assess the performance of these equations for their original 
intent. Also, our study population consists exclusively of 
Caucasian females, and the findings of this analysis should 
not be extrapolated to other patient populations without 
further analysis.
Conclusion
In summary, our study describes the performance of several 
formulae for the estimation of FFW measured by DEXA body 
composition scanning in a cohort of morbidly obese females. 
The FFM[Garrow] equation provides the best estimation of the 
measured FFM. The findings have important potential clinical 
implications as they relate to effective and safe medication 
dosing and optimal nutritional care, both for the hospitalized 
patient and for the morbidly obese patient managed in the 
outpatient setting.
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